Idorsia Ltd (IDIA) - Total Liabilities
Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.66 Billion CHF (≈ $2.09 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Idorsia Ltd (IDIA) investment intensity to see how much of total assets are deployed in long-term investments.
Idorsia Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see IDIA total asset value.
Idorsia Ltd Competitors by Total Liabilities
The table below lists competitors of Idorsia Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TravelSky Technology Limited
F:TVL
|
Germany | €8.57 Billion |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
Israel | ILA466.68 Million |
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
Mexico | MX$6.75 Billion |
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
China | CN¥1.28 Billion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL13.28 Billion |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
China | CN¥942.80 Million |
|
Coretronic
TWO:5371
|
Taiwan | NT$29.79 Billion |
|
Baltic Classifieds Group PLC
LSE:BCG
|
UK | €95.38 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Idorsia Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Idorsia Ltd (2016–2025)
The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF1.60 Billion ≈ $2.03 Billion |
-6.69% |
| 2024-12-31 | CHF1.72 Billion ≈ $2.17 Billion |
+16.98% |
| 2023-12-31 | CHF1.47 Billion ≈ $1.86 Billion |
-6.16% |
| 2022-12-31 | CHF1.57 Billion ≈ $1.98 Billion |
+13.52% |
| 2021-12-31 | CHF1.38 Billion ≈ $1.74 Billion |
+62.23% |
| 2020-12-31 | CHF849.88 Million ≈ $1.07 Billion |
+1.19% |
| 2019-12-31 | CHF839.85 Million ≈ $1.06 Billion |
+12.11% |
| 2018-12-31 | CHF749.14 Million ≈ $947.12 Million |
+35.62% |
| 2017-12-31 | CHF552.37 Million ≈ $698.34 Million |
+35.67% |
| 2016-12-31 | CHF407.15 Million ≈ $514.75 Million |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more